Achaogen, Inc. (NASDAQ:AKAO) has been given an average rating of “Buy” by the thirteen ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $25.88.
Several equities analysts recently weighed in on the company. Stifel Nicolaus restated a “buy” rating and issued a $30.00 price target on shares of Achaogen in a research note on Friday, August 4th. BidaskClub lowered Achaogen from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Zacks Investment Research upgraded Achaogen from a “sell” rating to a “hold” rating and set a $27.00 price target for the company in a research note on Monday, July 17th. ValuEngine upgraded Achaogen from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Wedbush restated an “outperform” rating and issued a $28.00 price target on shares of Achaogen in a research note on Monday, April 24th.
Shares of Achaogen (NASDAQ AKAO) traded down 0.30% during mid-day trading on Friday, reaching $16.64. The company’s stock had a trading volume of 319,619 shares. The firm’s market cap is $702.76 million. Achaogen has a 12-month low of $3.65 and a 12-month high of $27.79. The firm’s 50-day moving average price is $21.34 and its 200 day moving average price is $22.10.
Achaogen (NASDAQ:AKAO) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by $0.18. Achaogen had a negative net margin of 281.88% and a negative return on equity of 86.24%. The company had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $2.69 million. During the same quarter in the previous year, the business posted ($0.87) EPS. The business’s quarterly revenue was down 85.7% on a year-over-year basis. On average, analysts expect that Achaogen will post ($3.00) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Achaogen, Inc. (NASDAQ:AKAO) Receives $25.98 Consensus PT from Analysts” was first reported by BNB Daily and is the property of of BNB Daily. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/analysts-set-achaogen-inc-nasdaqakao-price-target-at-25-98-updated-updated-updated.html.
In other news, CFO Tobin Schilke sold 2,066 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $21.53, for a total transaction of $44,480.98. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 13.80% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of AKAO. FMR LLC boosted its position in shares of Achaogen by 64.4% in the first quarter. FMR LLC now owns 4,778,253 shares of the biopharmaceutical company’s stock valued at $120,556,000 after buying an additional 1,871,764 shares in the last quarter. TimesSquare Capital Management LLC boosted its position in Achaogen by 106.7% in the second quarter. TimesSquare Capital Management LLC now owns 1,088,300 shares of the biopharmaceutical company’s stock worth $23,649,000 after buying an additional 561,700 shares in the last quarter. Vanguard Group Inc. boosted its position in Achaogen by 11.2% in the first quarter. Vanguard Group Inc. now owns 1,066,701 shares of the biopharmaceutical company’s stock worth $26,913,000 after buying an additional 107,406 shares in the last quarter. Franklin Resources Inc. acquired a new position in Achaogen during the second quarter worth approximately $8,692,000. Finally, Renaissance Technologies LLC boosted its position in Achaogen by 27.6% in the fourth quarter. Renaissance Technologies LLC now owns 377,200 shares of the biopharmaceutical company’s stock worth $4,911,000 after buying an additional 81,700 shares in the last quarter. Institutional investors and hedge funds own 70.30% of the company’s stock.
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.